Advertisement
Australia markets open in 2 hours 38 minutes
  • ALL ORDS

    7,831.90
    -100.10 (-1.26%)
     
  • AUD/USD

    0.6524
    +0.0045 (+0.69%)
     
  • ASX 200

    7,569.90
    -94.20 (-1.23%)
     
  • OIL

    79.13
    -2.80 (-3.42%)
     
  • GOLD

    2,330.20
    +27.30 (+1.19%)
     
  • Bitcoin AUD

    88,289.41
    -3,963.37 (-4.30%)
     
  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

Earlier this month, Merck (NYSE: MRK) announced it was ending clinical trials of its antiviral pill candidate for treating COVID-19, molnupiravir, on account of the potential therapy's high level of effectiveness. Take Gilead Sciences' (NASDAQ: GILD) antiviral drug, remdesivir. Will Merck's drug follow a similar or better path?